Clinical Trial Update: Ticagrelor vs. Prasugrel Effects on Infarct Size [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing ticagrelor and prasugrel for effects on infarct size in cardiovascular disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease

Drugs mentioned

• PRASUGREL (prasugrel)
• TICAGRELOR (ticagrelor)

Snippet

Sponsor: Yochai Birnbaum | Conditions: Cardiovascular Disease | Phase 2 | Status: WITHDRAWN